Immuneering Corporation IMRX

Set alert

Price alert · IMRX

All alert types
3.49 USD -0.25 -6.81%

At close · Nov 2

3.50 +0.01 +0.29%

After hours · Nov 2, 4:00 PM ET

Bid
3.50 × 2
Ask
3.51 × 2
3.45 Day range 3.94
3.38 52-week range 8.48
YTD
-46.96%
1 year
-49.20%
Open
3.76
Prev close
3.75
Mkt cap
226.02M
Vol
799.88K
Avg vol
714.14K
EPS
-0.92
P/E
0.00
Div yield
0.00%
More statistics
Low
3.45
High
3.94
Forward P/E
-1.34
Beta
-0.40
Short ratio
1.19
Inst. own
30.11%
Dividend
0.00
Ex-div date
Earnings
Aug 6, 2024
50-d avg
2.01
200-d avg
1.84
1y target
12.42

1D chart

Chart tools
Interval

Signals (48)
NameTimeAgo
MACD: Buy Signal3:36 PM14 hours ago
RSI: Oversold3:32 PM14 hours ago
MACD: Sell Signal3:12 PM14 hours ago
MACD: Buy Signal3:09 PM14 hours ago
SMA: Bullish3:08 PM14 hours ago
SMA: Bearish3:04 PM14 hours ago
SMA: Bullish3:03 PM14 hours ago
SMA: Bearish3:01 PM15 hours ago
SMA: Bullish2:58 PM15 hours ago
MACD: Sell Signal2:49 PM15 hours ago
RSI: Overbought2:41 PM15 hours ago
MACD: Buy Signal2:38 PM15 hours ago
MACD: Sell Signal2:36 PM15 hours ago
SMA: Bullish2:27 PM15 hours ago
SMA: Bullish2:24 PM15 hours ago
MACD: Buy Signal2:08 PM15 hours ago
MACD: Sell Signal1:57 PM16 hours ago
MACD: Buy Signal1:52 PM16 hours ago
RSI: Oversold1:38 PM16 hours ago
MACD: Sell Signal1:27 PM16 hours ago

Newest 20 of 48.

Analyst view

Consensus: buy

Buy
Price target (mean) 12.42 +255.8% upside
Target (low)
1.50
Target (mean)
12.42
Target (high)
25.00
Ratings (0m) 7 5 buy · 1 hold · 1 sell
  • Strong buy2
  • Buy3
  • Hold1
  • Sell1
  • Strong sell0

Recommendation trend

  • This month 7
  • 1 month ago 7
  • 2 months ago 7
  • 3 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

IMRX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.39167-0.59 – -0.23-0.52+24.7%00.0%6
Next quarter-0.41-0.41 – -0.41-0.49+16.3%00.0%1
Current year-1.79-2.05 – -1.47-1.88+4.6%00.0%6
Next year-1.63-2.36 – -0.92-1.79+9.2%00.0%5

Upgrades and downgrades

The latest rating changes

IMRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2024Chardan CapitalMaintainedBuyBuy
Nov 14, 2024NeedhamReiteratedBuyBuy
Sep 13, 2024NeedhamReiteratedBuyBuy
Aug 7, 2024Chardan CapitalMaintainedBuyBuy
Aug 7, 2024NeedhamReiteratedBuyBuy
May 8, 2024NeedhamReiteratedBuyBuy
Apr 12, 2024NeedhamReiteratedBuyBuy
Apr 2, 2024MizuhoMaintainedBuyBuy
Mar 15, 2024JefferiesDowngradeBuyHold
Mar 15, 2024Chardan CapitalMaintainedBuyBuy
Mar 15, 2024NeedhamMaintainedBuyBuy
Mar 15, 2024TD CowenDowngradeOutperformMarket Perform
Mar 14, 2024GuggenheimDowngradeBuyNeutral
Mar 11, 2024NeedhamReiteratedBuyBuy
Mar 5, 2024OppenheimerReiteratedOutperformOutperform
Mar 4, 2024NeedhamReiteratedBuyBuy
Feb 1, 2024NeedhamReiteratedBuyBuy
Dec 1, 2023NeedhamInitiated—Buy
Aug 8, 2023OppenheimerReiteratedOutperformOutperform
Aug 7, 2023Chardan CapitalReiteratedBuyBuy
Aug 4, 2023Morgan StanleyMaintainedEqual-WeightEqual-Weight
Apr 19, 2023Morgan StanleyUpgradeUnderweightEqual-Weight
Apr 19, 2023MizuhoUpgradeNeutralBuy
Apr 19, 2023Chardan CapitalMaintained—Buy
Apr 18, 2023Chardan CapitalMaintained—Buy
Mar 30, 2023MizuhoInitiated—Neutral
Mar 7, 2023Chardan CapitalReiterated—Buy
Feb 3, 2023Morgan StanleyDowngradeEqual-WeightUnderweight
Jul 15, 2022Morgan StanleyMaintained—Equal-Weight
Jul 8, 2022Chardan CapitalInitiated—Buy